Data updated: Jun 28, 2026
Alopecia Clinical Trial Landscape
Alopecia is being studied across 254 clinical trials registered since 2008, with 78 programs currently active. The competitive pipeline includes 25 active Phase 3 trials, 37 active Phase 2 trials, and 7 active Phase 1 trials.
Top industry sponsors include Applied Biology, Inc., Veradermics, Inc., Pfizer.
Trial activity
78 active / 254 total since 2008
Active by phase 25 Ph3 / 63 37 Ph2 / 135 7 Ph1 / 33 9 Ph4 / 23
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Applied Biology, Inc. 4 0 1
Veradermics, Inc. 4 0 0
Pfizer 3 5 1
AbbVie 2 7 1
Eli Lilly 2 2 0
Eurofarma Laboratorios S.A. 2 1 0
Sun Pharmaceutical Industries, Inc. 2 1 0
Suzhou Kintor Pharmaceutical Inc, 1 7 0
Chong Kun Dang Pharmaceutical 1 3 0
Industrial Farmacéutica Cantabria, S.A. 1 0 0
Dren Bio 1 0 0
Absci Pty Ltd. 1 0 0
Q32 Bio Inc. 1 0 0
Innovent Biologics (Suzhou) Co. Ltd. 1 0 0
NEXTGEN Bioscience 1 0 0
How the field has grown
New-trial starts peaked in 2025 (32 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (49 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 15
2017 6
2018 15
2019 13
2020 13
2021 15
2022 23
2023 22
2024 19
2025 32
2026 23
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (2) 233
2017 (0) 0
2018 (5) 675
2019 (3) 1,000
2020 (3) 75
2021 (5) 407
2022 (1) 315
2023 (8) 466
2024 (5) 480
2025 (13) 288
2026 (4) 378
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT06873945 ACTIVE NOT RECRUITING
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer n=550
NCT06012240 RECRUITING
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie n=1,500
NCT05888922 RECRUITING
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Industrial Farmacéutica Cantabria, S.A. n=520
NCT07029828 RECRUITING
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer n=140
NCT05723198 RECRUITING
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company n=595
NCT07529977 NOT YET RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
Eurofarma Laboratorios S.A. n=372
NCT07516561 NOT YET RECRUITING
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
Apsen Farmaceutica S.A. n=336
NCT06648850 NOT YET RECRUITING
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Applied Biology, Inc. n=1,120
NCT07029711 ACTIVE NOT RECRUITING
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Pfizer n=208
NCT07080931 RECRUITING
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. n=294
NCT06972264 ACTIVE NOT RECRUITING
Safety and Efficacy of VDPHL01 in Males With AGA
Veradermics, Inc. n=480
NCT07133308 RECRUITING
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc. n=355
NCT07303322 NOT YET RECRUITING
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
Eurofarma Laboratorios S.A. n=372
NCT07023302 RECRUITING
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
AbbVie n=123
NCT07273799 NOT YET RECRUITING
Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia
Sheikh Zayed Federal Postgraduate Medical Institute n=200
NCT04594018 RECRUITING
Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia
EMS n=190
NCT07146022 RECRUITING
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
Veradermics, Inc. n=552
NCT06724614 ACTIVE NOT RECRUITING
Efficacy and Safety of VDPHL01 in Males With AGA
Veradermics, Inc. n=480
NCT03898479 ACTIVE NOT RECRUITING
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Sun Pharmaceutical Industries, Inc. n=1,000
NCT06762548 NOT YET RECRUITING
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia
Applied Biology, Inc. n=140
NCT06916793 NOT YET RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Chong Kun Dang Pharmaceutical n=288
NCT06501924 NOT YET RECRUITING
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
Applied Biology, Inc. n=516
NCT06622824 NOT YET RECRUITING
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
Suzhou Kintor Pharmaceutical Inc, n=756
NCT07617597 NOT YET RECRUITING
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Sun Pharma Japan Limited n=78
NCT06924632 COMPLETED
Efficacy & Safety of Minoxidil SL Tablets in Men With AGA
Samson Clinical Operations Pty Ltd n=142
NCT03570749 COMPLETED
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Eli Lilly and Company n=784
NCT03899259 COMPLETED
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
Eli Lilly and Company n=606
NCT02557074 COMPLETED
TREg Activation in the Treatment of the PELADE (Alopecia Areata)
Centre Hospitalier Universitaire de Nice n=44
NCT05910450 COMPLETED
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
Cassiopea SpA n=703
NCT05914805 COMPLETED
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
Cassiopea SpA n=762
NCT05041803 COMPLETED
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Sun Pharmaceutical Industries, Inc. n=407
NCT05255237 COMPLETED
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=315
NCT05051761 COMPLETED
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=425
NCT04721548 COMPLETED
Treatment of Androgenetic Alopecia in Men for 24 Weeks
Eurofarma Laboratorios S.A. n=336
NCT06484881 WITHDRAWN
Clinical Study of Probiotic Treatment for Androgenetic Alopecia
Applied Biology, Inc.
NCT06278402 COMPLETED
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
Jinnah Hospital n=30
NCT03240627 COMPLETED
Efficacy and Safety of LH-8 in Paediatric Alopecia Areata
Legacy Healthcare SA n=107
NCT05989165 COMPLETED
Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men
Indonesia University n=36
NCT04797650 COMPLETED
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
Concert Pharmaceuticals n=517
NCT04518995 COMPLETED
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Concert Pharmaceuticals n=706
NCT05296863 COMPLETED
Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia
Dr. dr. Lili Legiawati, SpKK(K) n=37
NCT03742518 COMPLETED
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
Biosplice Therapeutics, Inc. n=675
NCT03753113 COMPLETED
Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%
Farid Masoud n=24
NCT03004469 COMPLETED
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
Polichem S.A. n=458
NCT02014584 COMPLETED
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Stiefel, a GSK Company n=117
NCT01231607 COMPLETED
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
GlaxoSmithKline n=917
NCT01831791 COMPLETED
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
GlaxoSmithKline n=120
NCT02037191 COMPLETED
The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade
University Hospital, Rouen n=90
NCT01590238 COMPLETED
Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
The New York Eye & Ear Infirmary n=15
NCT01226459 COMPLETED
Clinical Trial in Females for Female Pattern Hair Loss
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. n=404
NCT01145625 COMPLETED
Clinical Trial in Females With Female Pattern Hair Loss
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. n=322
NCT00997815 COMPLETED
The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis
Siriraj Hospital n=20
NCT01391156 COMPLETED
Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss
Mae Fah Luang University Hospital n=40
NCT00958750 COMPLETED
Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia
Charite University, Berlin, Germany n=113
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only